Fecha de publicación: -- Fuente: PubMed "olive oil" Naunyn Schmiedebergs Arch Pharmacol. 2026 Nov 5. doi: 10.1007/s00210-026-06039-5. Online ahead of print.ABSTRACTThis study aimed to develop mannosylated nanostructured lipid carriers loaded with Thiabendazole for intravenous delivery to prevent lung biofilm formation. Mannosylated NLCs combine the targeting capabilities of mannose-functionalized carriers with the favorable physicochemical properties of NLCs. Mannose-coated NLCs (MCT-NLCs), prepared via microemulsification using Glyceryl monostearate, olive oil, and Geraniol, had an approximate size of 240 nm, a zeta potential of about - 32.5 mV, an entrapment efficiency of 96%, and released about 84% of the drug within 24 h. Microscopy showed spherical particles under 250 nm, supported by thermal and diffraction analyses. TEM and IR spectra confirmed surface mannose. In vitro, they demonstrated sustained drug release compared to free drug. After IV administration, these NLCs reduced bacterial counts and minimized lung tissue damage in rats infected with Pseudomonas aeruginosa over seven days, demonstrating improved initial in vivo results, though they did not eradicate the infection. This study did not evaluate the formulation's safety, as it is a repurposed work. In vivo, the NLCs significantly lowered bacterial load and inflammation in a rat model of inhaled Pseudomonas aeruginosa biofilms relevant to cystic fibrosis over seven days, indicating potential to reduce bacterial contamination and tissue damage, although their targeting mechanism and ability to cure were not confirmed.PMID:42986396 | DOI:10.1007/s00210-026-06039-5